SCHEMBL6777367

SCHEMBL6777367

CCOC(=O)N=C(NC(=O)OCC)Nc1cccc(C(=O)NCC(=O)NC(Cc2cc(Cl)cc(Cl)c2)C(=O)OC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
NPSR1 Q6W5P4 4/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 3/20 0.39
NTSR1 P30989 1/20 0.39
ITGB1 P05556 2/20 0.38
ITGA5 P08648 1/20 0.38
GPR139 Q6DWJ6 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ATM Q13315 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
CTSL P07711 1/20 0.36
ITGB3 P05106 2/20 0.36
ITGAV P06756 2/20 0.36
ITGA2B P08514 1/20 0.36
ITGB5 P18084 1/20 0.36
NPFFR1 Q9GZQ6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7832173 0.91 ITGB1 (0.45) MAPTITGB1ITGA5GPR139MEN1
SCHEMBL6777366 0.86 GPR139 (0.38) MAPTITGB1ITGA5GPR139MEN1
SCHEMBL6777365 0.86 GPR139 (0.38) MAPTITGB1ITGA5GPR139MEN1
SCHEMBL6777796 0.82 ITGB3 (0.46) ITGB1ITGA5GPR139MEN1KMT2A
SCHEMBL6777799 0.82 ITGB3 (0.46) ITGB1ITGA5GPR139MEN1KMT2A
SCHEMBL7832444 0.75 NAMPT (0.48) MAPTMAPK1ITGB1ITGA5GPR139
SCHEMBL6773066 0.74 CTSS (0.44) MAPTNPSR1KDM4ETDP1GPR139
SCHEMBL7344520 0.73 CTSV (0.40) NPSR1ITGB1ITGA5GPR139MEN1
SCHEMBL7837655 0.73 NAMPT (0.59) KMT2A
SCHEMBL23455485 0.73 ITGB1 (0.52) MAPTNPSR1KDM4EITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed